The Pear-Bio assay uses a fresh tumour sample from the patient and a 3D hydrogel matrix to perform ex-vivo testing of treatments on each patient's tumour sample. We use matched blood samples to allow us to study the effects of immunotherapy.
Our aim is to develop a functional precision medicine assay to predict the impact of different therapies on patients' cancers, and so guide treatment selection
|
Our current clinical trials should allow us to develop, and perform initial validation on our assays in a limited number of cancers. Once we can show that we can reliably culture tumour cells in our system, we work on measuring how well our assay predicts response to different treatments.
Once we have that data, we will use it to plan our next round of clinical trials, with the eventual aim of showing that our platform can improve patient outcomes.
|